Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Drug Pipeline

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. maintains a substantial clinical portfolio, with 37 registered trials since 2008, 32 of which are currently active. Clinical activity spans early- to late-stage development, with 13 active Phase 1 trials, 13 in Phase 2, and 10 in Phase 3. The portfolio is heavily concentrated in oncology, which accounts for 28 active trials, representing 88% of the company's active programs. Within oncology, the leading indications are advanced solid tumors, with 11 active trials, followed by non-small cell lung cancer (NSCLC), with 5 active trials including 4 in Phase 3. Breast cancer is another area of focus, with 4 active trials, including 2 in Phase 3, as well as triple negative breast cancer with 3 active trials, including 2 in Phase 3. The remaining active trial is in immunology. The significant number of Phase 3 trials in NSCLC, breast cancer, and triple negative breast cancer suggests a potential for near-term clinical catalysts.